Assessing reduced-dose pneumococcal vaccine schedules in South Africa

Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial

“…The first two relate to the added advantages that a 1 + 1 schedule offers over a 0 + 1 schedule. Low-income and middle-income countries (LMICs) tend to have higher residual vaccine-type carriage following PCV introduction than high-income countries, 21 leaving children at greater risk of pneumococcal disease. When considering a switch to a reduced-dose schedule, the probable protection offered by the first dose in a 1 + 1 schedule is an important factor.…”

Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial

“…This is particularly pertinent in settings where there remains a modest prevalence of residual vaccine-serotype colonisation up to a decade after the introduction of PCVs into routine childhood immunisation programmes. 9 The prevalence of PCV13 colonisation in children younger than 5 years was 21·9% in 2017, mainly dominated by serotype 19F colonisation (11·6%), in South Africa. 10 In 2021, the colonisation prevalence of PCV13 in children younger than 5 years was 13·4% (unpublished).…”